SEELAS Life Sciences (US:SLS) Defense World·2026-01-03 07:34Core Viewpoint - SELLAS Life Sciences Group is experiencing mixed analyst ratings, with a consensus price target of $7.00 and a recent downgrade to a "sell (d-)" rating by Weiss Ratings [1] Insider Activity - Director Katherine Bach Kalin purchased 63,400 shares at an average price of $1.59, totaling $100,806, increasing her ownership by 154.63% to 104,400 shares valued at approximately $165,996 [2][3] Institutional Trading - Bank of America Corp DE increased its position by 21.9%, owning 42,150 shares worth $68,000 after acquiring 7,571 shares [4] - BNP Paribas Financial Markets boosted its stake by 89.2%, now owning 19,724 shares valued at $32,000 after purchasing 9,299 shares [4] - Opus Capital Group LLC increased its stake by 4.2%, owning 250,000 shares worth $403,000 after acquiring 10,000 shares [4] - Equitable Holdings Inc. raised its holdings by 58.6%, now owning 27,060 shares valued at $44,000 after purchasing 10,000 shares [4] - Axxcess Wealth Management LLC acquired a new stake valued at about $26,000 [4] - Institutional investors own 17.38% of the stock [4] Stock Performance - The stock opened at $4.35, with a market capitalization of $619.61 million, a PE ratio of -15.54, and a beta of 2.26 [5] - The 52-week low is $0.85 and the high is $4.66 [5] Earnings Results - The company reported earnings per share (EPS) of ($0.06), exceeding the consensus estimate of ($0.08) by $0.02 [6] - Analysts forecast an EPS of -$0.57 for the current year [6] Options Trading - There was a significant increase in options trading, with 149,934 call options bought, representing an increase of approximately 829% compared to the average volume [8] Company Overview - SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing active cellular immunotherapies for cancer, particularly targeting the WT1 antigen [9] - The lead product candidate is galinpepimut-S (GPS), an investigational multi-peptide vaccine directed against WT1 [10]